Pembrolizumab for Early Triple-Negative Breast CancerPeter Schmid, Joyce O’Shaughnessy, Rina Hui et al.|New England Journal of Medicine|2020Cited by 3.1k
Current Landscape of Immunotherapy in Breast CancerSylvia Adams, Elizabeth A. Mittendorf, Margaret E. Gatti‐Mays et al.|JAMA Oncology|2019Cited by 409
Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancerDavid B. Page, Sylvia Adams, Harry D. Bear et al.|npj Breast Cancer|2019Cited by 86
A phase Ib trial of pembrolizumab plus paclitaxel or flat-dose capecitabine in 1st/2nd line metastatic triple-negative breast cancerDavid B. Page, Heather L. McArthur|npj Breast Cancer|2023Cited by 7